Artwork

Content provided by Jody Marks, MSN, AGACNP-BC, FNP-BC, Jody Marks, and MSN. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jody Marks, MSN, AGACNP-BC, FNP-BC, Jody Marks, and MSN or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

A New(-ish) Antacid Medication

11:49
 
Share
 

Manage episode 437593486 series 3476336
Content provided by Jody Marks, MSN, AGACNP-BC, FNP-BC, Jody Marks, and MSN. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jody Marks, MSN, AGACNP-BC, FNP-BC, Jody Marks, and MSN or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

The new PCAB Voquenza (vonoprazan) is being marketed as a superior alternative to PPI therapy for acid-related conditions (GERD with or without erosive esophagitis, H. pylori eradication). Are these two mechanisms of action really that different? Jody investigates.

References:

1) Prescriber information: https://www.phathompharma.com/wp-content/uploads/VOQUEZNA-tablets-Prescriber-Information.pdf

2) György Miklós Buzás, Dual acid-pump blocking as novel therapeutic approach to treatment of acid-related diseases, Medical Hypotheses, Volume 187, 2024, 111338, ISSN 0306-9877, https://doi.org/10.1016/j.mehy.2024.111338.

3) Katzka DA, Kahrilas PJ. Potassium-Competitive Acid Blocker Suppression of Gastric Acid in Erosive Esophagitis: Is Stronger and Longer Better? Gastroenterology. 2023 Jan;164(1):14-15. doi: 10.1053/j.gastro.2022.10.022. Epub 2022 Oct 28. PMID: 36341738.

4) Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008 Dec;10(6):528-34. doi: 10.1007/s11894-008-0098-4. PMID: 19006606; PMCID: PMC2855237.

5) Simadibrata DM, Syam AF, Lee YY. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2022 Dec;37(12):2217-2228. doi: 10.1111/jgh.16017. Epub 2022 Oct 26. PMID: 36181401; PMCID: PMC10092067.

6) Oshima T, Miwa H. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. J Neurogastroenterol Motil. 2018 Jul 30;24(3):334-344. doi: 10.5056/jnm18029. PMID: 29739175; PMCID: PMC6034668

  continue reading

80 episodes

Artwork
iconShare
 
Manage episode 437593486 series 3476336
Content provided by Jody Marks, MSN, AGACNP-BC, FNP-BC, Jody Marks, and MSN. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jody Marks, MSN, AGACNP-BC, FNP-BC, Jody Marks, and MSN or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

The new PCAB Voquenza (vonoprazan) is being marketed as a superior alternative to PPI therapy for acid-related conditions (GERD with or without erosive esophagitis, H. pylori eradication). Are these two mechanisms of action really that different? Jody investigates.

References:

1) Prescriber information: https://www.phathompharma.com/wp-content/uploads/VOQUEZNA-tablets-Prescriber-Information.pdf

2) György Miklós Buzás, Dual acid-pump blocking as novel therapeutic approach to treatment of acid-related diseases, Medical Hypotheses, Volume 187, 2024, 111338, ISSN 0306-9877, https://doi.org/10.1016/j.mehy.2024.111338.

3) Katzka DA, Kahrilas PJ. Potassium-Competitive Acid Blocker Suppression of Gastric Acid in Erosive Esophagitis: Is Stronger and Longer Better? Gastroenterology. 2023 Jan;164(1):14-15. doi: 10.1053/j.gastro.2022.10.022. Epub 2022 Oct 28. PMID: 36341738.

4) Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008 Dec;10(6):528-34. doi: 10.1007/s11894-008-0098-4. PMID: 19006606; PMCID: PMC2855237.

5) Simadibrata DM, Syam AF, Lee YY. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2022 Dec;37(12):2217-2228. doi: 10.1111/jgh.16017. Epub 2022 Oct 26. PMID: 36181401; PMCID: PMC10092067.

6) Oshima T, Miwa H. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. J Neurogastroenterol Motil. 2018 Jul 30;24(3):334-344. doi: 10.5056/jnm18029. PMID: 29739175; PMCID: PMC6034668

  continue reading

80 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Listen to this show while you explore
Play